Nordic Nanovector Announces Update from Archer-1 Phase 1b Trial of Betalutin® in combination with rituximab in 2L Follicular Lymphoma
Oslo, Norway, 25 May 2021 Nordic Nanovector ASA (OSE: NANOV) announces initial promising data from the Archer-1 Phase 1b trial investigating Betalutin® ([177]Lu lilotomab satetraxetan) in combination with rituximab (RTX) in second-line follicular lymphoma (2L FL). The preliminary results show clinical activity with seven out of seven patients achieving a response, including 5 complete responses and 2 partial responses. All responses are currently ongoing, 5 of them 2 years after Betalutin® administration. Across this patient group, Betalutin® with RTX showed a very good safety